유방암 액체생검 시장 : 성장, 동향, 예측
Breast Cancer Liquid Biopsy Market - Growth, Trends, and Forecast (2020 - 2025)
상품코드 : 925256
리서치사 : Mordor Intelligence LLP
발행일 : 2020년 02월
페이지 정보 : 영문
US $ 4,250 ₩ 5,020,000
PDF by E-mail (Single User License)
US $ 4,750 ₩ 5,611,000
PDF by E-mail (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,087,000
PDF by E-mail (Site License)
US $ 7,500 ₩ 8,859,000
PDF by E-mail (Corporate License)


한글목차

세계의 유방암 액체생검(Breast Cancer Liquid Biopsy) 시장은 2020-2025년 18.9% 이상의 CAGR로 확대될 것으로 예측됩니다. 유방암의 유병률 상승과 저침습 치료법에 대한 수요의 증가가 시장을 촉진하고 있습니다.

세계의 유방암 액체생검 시장을 조사했으며, 시장의 개요, 유형, 지역별 시장 동향, 시장 규모의 추이와 예측, 시장 촉진·저해요인 및 시장 기회 분석, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

제5장 시장 세분화

제6장 경쟁 구도

제7장 시장 기회 및 향후 전망

KSA 20.05.15
영문 목차

영문목차

The Breast Cancer Liquid Biopsy Market is expected to register a CAGR of 18.9% during the forecast period. Breast cancer liquid biopsy is the method of detecting or investigating tumor cells in the blood sample obtained from the target cancerous site. For the detection of breast cancer, traditional methods like tissue biopsies are not comprehensive enough to predict or capture the entire genomics landscape of breast tumors. However, the presence of liquid biopsy as an alternative method allows for many clinical applications, including screening, detection of mutations, therapy selection, disease prognosis and drug response and resistance in patients who are unable to undergo an invasive tumor biopsy. According to World Health Organization (WHO), breast cancer is the most frequent type of cancer among women globally, approximately 2.1 million women suffer from breast cancer every year, and it leads to highest number of cancer-related deaths among women. In the year 2018, it was estimated that approximately 627,000 women died from breast cancer that is nearly 15% of all cancer deaths among women globally. Rising prevalence of breast cancer and increasing demand for better minimally invasive therapies are the key driving factors in breast cancer liquid biopsy market.

Key Market Trends

Circulating Cell-free DNA (cfDNA) Segment is Expected to Hold a Major Market Share in the Breast Cancer Liquid Biopsy Market

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global breast cancer liquid biopsy market due to the rising incidence of breast cancer cases and growing demand for non-invasive treatment in this region. According to the National Breast Cancer Foundation, in the year 2019, 62% of breast cancer cases were diagnosed at a localized stage. Female breast cancer represents approximately 15.2% of all new cancer cases in the United States. Furthermore, the high adoption rates of advanced diagnostic technologies such as PCR and NGS among healthcare professionals and presence of well-established healthcare infrastructure is fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Breast Cancer Liquid Biopsy Market is highly fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are QIAGEN, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Janssen Diagnostics, Biocept Inc, Guardant Health, Inc, Myriad Genetics, Adaptive Biotechnologies, Epic Sciences and Illumina, Inc.

Reasons to Purchase this report:

Table of Contents

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

5 MARKET SEGMENTATION

6 COMPETITIVE LANDSCAPE

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

(주)글로벌인포메이션 02-2025-2992 koreainfo@gii.co.jp
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기